Video

Dr. Galsky explains results of pivotal adjuvant immunotherapy trials in urothelial cancer

Matthew Galsky, MD, discusses the discordant results of the pivotal phase 3 CheckMate-274 and IMvigor010 trials of adjuvant immunotherapy in urothelial cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      In an interview during the SUO 23rd Annual Meeting, Matthew Galsky, MD, discussed the pivotal phase 3 CheckMate-274 IMvigor010 trials, and the how the results of the studies yielded discordant outcomes regarding the efficacy of adjuvant immunotherapy in urothelial cancer.

      Galsky is a professor of Medicine and director of Genitourinary Medical Oncology at the Icahn School of Medicine, Mount Sinai, and the co-director of the Center of Excellence for Bladder Cancer and associate director for translational research at the Tisch Cancer Institute.

      © 2025 MJH Life Sciences

      All rights reserved.